Pharmacokinetics of intravenous linezolid in moderately to morbidly obese adults.
about
Antibiotic therapy of pneumonia in the obese patient: dosing and deliveryDosing of antibacterial agents in obese adults: does one size fit all?Clinical population pharmacokinetics and toxicodynamics of linezolid.Pediatric Obesity: Pharmacokinetic Alterations and Effects on Antimicrobial Dosing.Applicability of a Single Time Point Strategy for the Prediction of Area Under the Concentration Curve of Linezolid in Patients: Superiority of Ctrough- over Cmax-Derived Linear Regression ModelsPredictors of Inadequate Linezolid Concentrations after Standard Dosing in Critically Ill Patients.Antibiotic dosing in obesity: the search for optimum dosing strategies.Drug monitoring and individual dose optimization of antimicrobial drugs: oxazolidinones.Critical role of tedizolid in the treatment of acute bacterial skin and skin structure infectionsClinical Determinants of Target Non-Attainment of Linezolid in Plasma and Interstitial Space Fluid: A Pooled Population Pharmacokinetic Analysis with Focus on Critically Ill Patients.Systematic Therapeutic Drug Monitoring for Linezolid: Variability and Clinical Impact.Linezolid plasma and intrapulmonary concentrations in critically ill obese patients with ventilator-associated pneumonia: intermittent vs continuous administration.Dosing strategies to optimize currently available anti-MRSA treatment options (Part 2: PO options).Clinical Pharmacokinetics and Pharmacodynamics of Oxazolidinones.Population Pharmacokinetics and Dosing Considerations for the Use of Linezolid in Overweight and Obese Adult Patients.A 10-Year Experience of Therapeutic Drug Monitoring (TDM) of Linezolid in a Hospital-wide Population of Patients Receiving Conventional Dosing: Is there Enough Evidence for Suggesting TDM in the Majority of Patients?Steady-state pharmacokinetics of oral linezolid suspension in a premature infant with osteomyelitis.
P2860
Q29248400-3FD73492-F1E4-4702-A885-82083D9ECC7BQ30362353-A0584F9D-0E35-457E-8C85-46E3965DD3BBQ33413269-22A95F01-372D-4BDC-AA4E-F9E0DB2E34E8Q36247129-627D455F-23B5-4D47-AB34-D7A28EC913EEQ36620071-B67F03B5-4778-4468-B0A4-1DC6F4A8C51FQ37203803-205B98B6-EEFB-46F6-9AA8-C3FD415A6A0EQ38397264-1204783E-ACD3-49AA-A03C-8093146F70BEQ38777085-2181C8A9-FBD9-4DC8-98D1-01C980E0BFA7Q39067666-91163A1B-FCAA-4CDA-AEC0-6D1F303BE121Q39278957-8A19F134-BD78-4729-A12D-AC3EEEEB59D3Q40121784-87B46DBD-D9E2-4990-8551-A65F97846CF6Q41654159-C4EF442D-1419-40D3-A364-B54099B9AE47Q47396324-1C67E367-2372-40CE-ABDB-0242D6DE2CC1Q47611899-ACA88458-CDE1-4399-BDA1-47557381946CQ48108947-F5E63DC8-2AA4-4C55-8DD7-6CF4E234B6F0Q50719557-E5BB501A-FB67-4EC4-B904-C92AD1C8A1F5Q54668056-68E8812D-F634-467A-AFCE-AFB544BC9542
P2860
Pharmacokinetics of intravenous linezolid in moderately to morbidly obese adults.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Pharmacokinetics of intravenous linezolid in moderately to morbidly obese adults.
@ast
Pharmacokinetics of intravenous linezolid in moderately to morbidly obese adults.
@en
type
label
Pharmacokinetics of intravenous linezolid in moderately to morbidly obese adults.
@ast
Pharmacokinetics of intravenous linezolid in moderately to morbidly obese adults.
@en
prefLabel
Pharmacokinetics of intravenous linezolid in moderately to morbidly obese adults.
@ast
Pharmacokinetics of intravenous linezolid in moderately to morbidly obese adults.
@en
P2093
P2860
P356
P1476
Pharmacokinetics of intravenous linezolid in moderately to morbidly obese adults.
@en
P2093
Amira A Bhalodi
Darren S Tishler
David P Nicolau
Joseph L Kuti
Pavlos K Papasavas
P2860
P304
P356
10.1128/AAC.01453-12
P407
P577
2012-12-17T00:00:00Z